@article{Wang2019, 
author = {Tao Wang and Jiuyang He and Demin Duan and Bing Jiang and Peixia Wang and Kelong Fan and Minmin Liang and Xiyun Yan},
title = {Bioengineered magnetoferritin nanozymes for pathological identification of high-risk and ruptured atherosclerotic plaques in humans},
year = {2019},
journal = {Nano Research},
volume = {12},
number = {4},
pages = {863-868},
keywords = {nanozymes, atherosclerosis, high-risk plaques, ruptured plaques, magnetoferritin nanoparticles, pathological diagnosis},
url = {https://www.sciopen.com/article/10.1007/s12274-019-2313-z},
doi = {10.1007/s12274-019-2313-z},
abstract = {Atherosclerotic plaque rupture results in thrombus formation and vessel occlusion, and is the leading cause of death worldwide. There is a pressing need to identify plaque vulnerability for the treatment of carotid and coronary artery diseases. Nanomaterials with enzyme-like properties have attracted significant interest by providing biological, diagnostic and prognostic information about the diseases. Here we showed that bioengineered magnetoferritin nanoparticles (M-HFn NPs) functionally mimic peroxidase enzyme and can intrinsically recognize plaque-infiltrated active macrophages, which drive atherosclerotic plaque progression and rupture and are significantly associated with the plaque vulnerability. The M-HFn nanozymes catalyze the oxidation of colorimetric substrates to give a color reaction that visualizes the recognized active macrophages for one-step pathological identification of plaque vulnerability. We examined 50 carotid endarterectomy specimens from patients with symptomatic carotid disease and demonstrated that the M-HFn nanozymes could distinguish active macrophage infiltration in ruptured and high-risk plaque tissues, and M-HFn staining displayed a significant correlation with plaque vulnerability (r = 0.89,  P < 0.0001).}
}